Evidence map›Paper›PMID 25522233›Full record

ArticlePLoS genetics2014

SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.

Bastien Gerby, Cedric S Tremblay, Mathieu Tremblay, Shanti Rojas-Sutterlin, Sabine Herblot, Josée Hébert, Guy Sauvageau, Sébastien Lemieux, Eric Lécuyer, Diogo F T Veiga and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
6.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. MonoallelicFrontiers in immunology · 2022
    Article
  17. Review
  18. Review
  19. Associations betweenPediatric investigation · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Bastien GerbyInstitute of Research in Immunology and Cancer - University of Montreal, Montreal, Quebec, Canada; Molecular Biology Program, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
Cedric S TremblayInstitute of Research in Immunology and Cancer - University of Montreal, Montreal, Quebec, Canada; Molecular Biology Program, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
Mathieu TremblayInstitute of Research in Immunology and Cancer - University of Montreal, Montreal, Quebec, Canada; Molecular Biology Program, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
Shanti Rojas-SutterlinInstitute of Research in Immunology and Cancer - University of Montreal, Montreal, Quebec, Canada; Molecular Biology Program, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
Sabine HerblotInstitute of Research in Immunology and Cancer - University of Montreal, Montreal, Quebec, Canada.
Josée HébertInstitute of Research in Immunology and Cancer - University of Montreal, Montreal, Quebec, Canada; Molecular Biology Program, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada; Maisonneuve-Rosemont Hospital. Montreal, Quebec, Canada.
Guy SauvageauInstitute of Research in Immunology and Cancer - University of Montreal, Montreal, Quebec, Canada; Molecular Biology Program, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada; Maisonneuve-Rosemont Hospital. Montreal, Quebec, Canada.
Sébastien LemieuxInstitute of Research in Immunology and Cancer - University of Montreal, Montreal, Quebec, Canada; Molecular Biology Program, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
Eric LécuyerClinical Research Institute of Montreal (IRCM), Montreal, Quebec, Canada; Department of Biochemistry, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
Diogo F T VeigaInstitute of Research in Immunology and Cancer - University of Montreal, Montreal, Quebec, Canada; Molecular Biology Program, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
Trang HoangInstitute of Research in Immunology and Cancer - University of Montreal, Montreal, Quebec, Canada; Molecular Biology Program, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada; Department of Biochemistry, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada; Department of Pharmacology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
Institute for Research in Immunology and Cancer · CAUniversité de Montréal · CAHôpital Maisonneuve-Rosemont · CAMontreal Clinical Research Institute · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

The molecular determinants that render specific populations of normal cells susceptible to oncogenic reprogramming into self-renewing cancer stem cells are poorly understood. Here, we exploit T-cell acute lymphoblastic leukemia (T-ALL) as a model to define the critical initiating events in this disease. First, thymocytes that are reprogrammed by the SCL and LMO1 oncogenic transcription factors into self-renewing pre-leukemic stem cells (pre-LSCs) remain non-malignant, as evidenced by their capacities to generate functional T cells. Second, we provide strong genetic evidence that SCL directly interacts with LMO1 to activate the transcription of a self-renewal program coordinated by LYL1. Moreover, LYL1 can substitute for SCL to reprogram thymocytes in concert with LMO1. In contrast, inhibition of E2A was not sufficient to substitute for SCL, indicating that thymocyte reprogramming requires transcription activation by SCL-LMO1. Third, only a specific subset of normal thymic cells, known as DN3 thymocytes, is susceptible to reprogramming. This is because physiological NOTCH1 signals are highest in DN3 cells compared to other thymocyte subsets. Consistent with this, overexpression of a ligand-independent hyperactive NOTCH1 allele in all immature thymocytes is sufficient to sensitize them to SCL-LMO1, thereby increasing the pool of self-renewing cells. Surprisingly, hyperactive NOTCH1 cannot reprogram thymocytes on its own, despite the fact that NOTCH1 is activated by gain of function mutations in more than 55% of T-ALL cases. Rather, elevating NOTCH1 triggers a parallel pathway involving Hes1 and Myc that dramatically enhances the activity of SCL-LMO1 We conclude that the acquisition of self-renewal and the genesis of pre-LSCs from thymocytes with a finite lifespan represent a critical first event in T-ALL. Finally, LYL1 and LMO1 or LMO2 are co-expressed in most human T-ALL samples, except the cortical T subtype. We therefore anticipate that the self-renewal network described here may be relevant to a majority of human T-ALL.

Indexed as

Cellular ReprogrammingAmino Acid SequenceAnimalsBasic Helix-Loop-Helix ProteinsCell ProliferationCell Transformation, NeoplasticDisease Models, AnimalGene Expression Regulation, NeoplasticGenetic LociLIM Domain ProteinsMiceMice, KnockoutMolecular Sequence DataMutationNeoplasm ProteinsNuclear ProteinsBasic Helix-Loop-Helix ProteinsLIM Domain ProteinsLmo1 protein, mouseLyl1 protein, mouseNeoplasm ProteinsNotch1 protein, mouseNuclear ProteinsProto-Oncogene ProteinsReceptor, Notch1Tal1 protein, mouseT-Cell Acute Lymphocytic Leukemia Protein 1Transcription Factors

Identifiers

PMID25522233
PMCPMC4270438
OpenAlexW2157536177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.